Cytokinetics Inc (US: CYTK) — Healthcare · Share Price, Chart & Market Data
About: Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $65.32 (-0.24%)
CYTKCytokinetics Inc
Loading watchlist status…
Trade CYTK now
Cytokinetics Inc share price
CYTK price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 11:14 am GMT+0
CYTK price performance
-0.729%
5D
4.512%
1M
5.816%
YTD
58.467%
1Y
CYTK price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 11:14 am GMT+0
CYTK details
CYTK Market Signals